报价延迟最少15分钟:2026/03/02 20:00 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
29.53 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.03/0.66
|
|
企业价值
3.00B
|
| 资产负债 |
|
每股账面净值
0.82
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
233.18M
|
|
每股收益
2.59
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body. |
